---
title: "China Meheco's subsidiary receives approval notice for the listing application of fumaric acid vorinostat chemical raw materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252808572.md"
description: "China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical has received the notice of approval for the listing application of fumaric acid volnorex biochemical raw materials from the National Medical Products Administration. This drug is mainly used to treat reflux esophagitis and can be used in combination with antibiotics to eradicate Helicobacter pylori. This approval marks that the raw material drug meets domestic drug registration requirements, further supporting the company's integrated development strategy of raw materials and formulations, expanding product areas, and accumulating experience for subsequent raw material drug applications"
datetime: "2025-08-13T08:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252808572.md)
  - [en](https://longbridge.com/en/news/252808572.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252808572.md)
generator: "portal-rs"
---

# China Meheco's subsidiary receives approval notice for the listing application of fumaric acid vorinostat chemical raw materials

According to the announcement from China Meheco (600056.SH), its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has recently received the Chemical Raw Material Drug Listing Application Approval Notice for Fumaric Acid Venlafaxine issued by the National Medical Products Administration (referred to as "NMPA"). This drug is primarily used for the treatment of reflux esophagitis and is used in conjunction with appropriate antibiotics to eradicate Helicobacter pylori.

The approval of the Fumaric Acid Venlafaxine chemical raw material drug listing application by Tianfang Pharmaceutical indicates that the raw material drug complies with the relevant regulatory requirements for domestic drug registration and has been approved for use in domestic formulations. The approval of this raw material drug will further solidify the company's integrated development strategy for raw materials and formulations, while also expanding the company's product areas and accumulating valuable experience for future raw material drug applications

### Related Stocks

- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)

## Related News & Research

- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [Biocytogen Pharmaceuticals announces extraordinary general meeting](https://longbridge.com/en/news/297148979.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [RCS - ZAGENO - ZAGENO and ORO Labs Partnership](https://longbridge.com/en/news/297046609.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**